1. The Nordic Women’s Health Hub

The hub was launched in February 2025 as a cross-Nordic platform connecting startups, researchers, investors, and industry to accelerate innovation and market maturity in women’s health, with Denmark as an initial anchor. The hub has recently received DKK 1 million from the Danish Industry Foundation to accelerate women’s health as a Danish business and innovation field. Initiatives include mapping the ecosystem and shaping the Women’s Health 2040 Vision.

2. The Nordic Charter for Women’s Health 2040

Resulting from the collective insight of over 130 contributors across Denmark, Norway, Sweden, Finland, and Iceland, gathering at Danish Parliament December 8, 2025, this document moves beyond aspiration to outline a concrete infrastructure for systemic change. A newly published The Lancet article on the charter underscores that women’s health has been structurally undervalued and must be reimagined.

3. The new Danish National Centre for Research in Women’s Health

The Danish government announced in October 2025 that it will allocate EUR 21.5 million over the next four years to the new research centre. With this multi-year effort to strengthen research in women’s health and women-related diseases, the aim is to establish a permanent focus on women’s health and generate critical scientific knowledge in this area.

4. The Women’s Health Hub in Finland

The hub was launched in Turku in 2024 and is a network of major pharmaceutical and diagnostics companies, researchers and public sector stakeholders aiming to accelerate advancement and innovation in women’s health on a global scale. Coordinated by the regional development company Business Turku, the network targets multibillion-euro export markets and attracts international investment.

Related article

New report: Unlocking investment in women’s health

Women’s health only receives 6% of private healthcare investment despite women representing almost half of the global population, according to a new World Economic Forum report, launched January 20 2026.

3 x Nordic women’s health Companies
  • Gesynta Pharma (Sweden) develops drug candidates with the aim to reduce harmful inflammation and pain. Its lead candidate vipoglanstat is a non-hormonal, potentially disease-modifying candidate that inhibits the inflammation-related enzyme mPGES-1. Vipoglanstat has entered a phase 2 clinical trial in patients with endometriosis.
  • MagCath (Denmark) is developing a silicone urethral device with a magnetic valve for controlling urination. The product allows women to wear it throughout the day without requiring replacement. A capital increase of DKK 4.1 million was closed Q1 2025. The proceeds will finance the market launch and the final stages of the CE-marking.
  • Gedea Biotech (Sweden) is a dedicated women’s health company developing pHyph, a novel, antibiotic‑free vaginal tablet that treats and helps prevent bacterial vaginosis (BV) by restoring vaginal pH and microbiome and breaking down BV biofilm. In March 2026 the company announced the start of the clinical study VVC2025, and the first patients have been enrolled.